Lucira Health, Inc.
LHDX · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | -0.28 | -1.65 | 0.00 |
| FCF Yield | -38.84% | -5.73% | -1.86% | -1.72% |
| EV / EBITDA | -3.24 | -29.26 | -51.45 | -65.76 |
| Quality | ||||
| ROIC | -33.68% | -37.88% | -216.36% | -400.12% |
| Gross Margin | 10.99% | -621.56% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.56 | 0.87 | 0.83 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -126.49% | -619.29% | -7.96% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.70 | 1.11 | 0.40 | -0.70 |
| Interest Coverage | -21,513.33 | -602.36 | -153.98 | -51.66 |
| Efficiency | ||||
| Inventory Turnover | 1.63 | 0.40 | 0.00 | 0.00 |
| Cash Conversion Cycle | 277.37 | 812.11 | 0.00 | 0.00 |